ConductScience.org, home
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
API referenceFor AI assistants

Trial · NCT00295932

Participant flow33

How many started, completed or left each group, period by period.

1 to 20 of 33

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTED1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide4
Overall StudySTARTED1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide6
Overall StudySTARTED1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide3
Overall StudySTARTED1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide4
Overall StudySTARTEDDose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid2
Overall StudySTARTEDDose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid18
Overall StudySTARTEDDose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham3
Overall StudySTARTEDDose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami4
Overall StudySTARTEDDose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami10
Overall StudySTARTEDWeekly Bortezomib Dosing Schedule12
Overall StudySTARTEDTwice-weekly Bortezomib Dosing Schedule13
Overall StudyCOMPLETED1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide4
Overall StudyCOMPLETED1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide6
Overall StudyCOMPLETED1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide3
Overall StudyCOMPLETED1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide4
Overall StudyCOMPLETEDDose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid2
Overall StudyCOMPLETEDDose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid18
Overall StudyCOMPLETEDDose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham3
Overall StudyCOMPLETEDDose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami4
Overall StudyCOMPLETEDDose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00295932/flow

API referenceFor AI assistants